Genentech, a member of the Roche Group (RHHBY), said that its risdiplam showed significant improvement in survival and motor milestones in infants with type 1 spinal muscular atrophy. The company
Continue reading »Home »
Home »
Genentech, a member of the Roche Group (RHHBY), said that its risdiplam showed significant improvement in survival and motor milestones in infants with type 1 spinal muscular atrophy. The company
Continue reading »